Results 141 to 150 of about 9,825 (155)

Sofosbuvir‐based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ERCHIVES

Liver International, 2016
Raymond Chung, Kenneth Sherman, Adeel Butt   +2 more
exaly  

Sofosbuvir Inhibits Hepatitis E Virus Replication In Vitro and Results in an Additive Effect When Combined With Ribavirin

Gastroenterology, 2016
Yannick Debing, Johan Neyts, Xianfang Wu   +2 more
exaly  

Ledipasvir–sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders

Haemophilia, 2017
Christopher Walsh
exaly  

Sofosbuvir/velpatasvir and sofosbuvir/velpatasvir/voxilaprevir

Reactions Weekly
openaire   +1 more source

Prices of sofosbuvir and ledipasvir/sofosbuvir unaffordable

PharmacoEconomics & Outcomes News, 2016
openaire   +1 more source

Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C

Journal of Hepatology, 2018
Peter Buggisch, Heiner Wedemeyer, Stefan Mauss   +2 more
exaly  

Sofosbuvir

Reactions Weekly, 2015
openaire   +2 more sources

Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential

Therapeutic Advances in Gastroenterology, 2014
Catherine Stedman
exaly  

Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison

Clinical Therapeutics, 2016
Caroline Geiger, James Signorovitch, Fan Mu   +2 more
exaly  

Simeprevir and Sofosbuvir for Treatment of Chronic Hepatitis C Infection

Clinical Therapeutics, 2015

exaly